Entrada Therapeutics is finally able to get its Duchenne muscular dystrophy candidate (DMD) back on track after the FDA ...

Entrada Therapeutics gains FDA clearance for its Phase 1b ELEVATE-44-102 study, evaluating ENTR-601-44 in adult Duchenne ...

Shares of Entrada Therapeutics rose after regulators removed a clinical hold and said its lead product candidate could be studied as a treatment for Duchenne muscular dystrophy. The stock was up 9.5% ...

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® ...

研究人员首次发现，人类细胞自带一套精密的"应急修复系统"，当检测到关键基因故障时，会自动激活"替补基因"展开修复。更令人振奋的是，这项机制可被人工干预精确调控，为DMD乃至6000多种单基因遗传病带来 ...

A 12-year-old boy with a severe form of muscular dystrophy has said it is "cruel" that a new drug is not being made available ...

转录适应上调杜氏肌营养不良症（DMD）患者的UTRN，这得到了几条证据的支持，包括使用剪接开关反义寡核苷酸诱导DMD基因框外外显子的跳跃。

Entrada Therapeutics (TRDA) announced that the United States Food and Drug Administration has lifted the clinical hold on ENTR-601-44 and ...

Receives FDA authorization to initiate ELEVATE-44-102, a Phase 1b multiple ascending dose clinical study of ENTR-601-44 in adults living with Duchenne muscular dystrophy – – Follows recently received ...

The company raised $200 million after early findings hinted its therapy could be more potent than others like it, including ...

Solid said that the first patients to receive its Duchenne gene therapy all produced high levels of the target protein, an ...

Its expansion is attributed to the treatment of ambulatory DMD patients. The Duchenne muscular dystrophy (DMD) market across ...